KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Payables (2016 - 2025)

Historic Payables for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$21.9 billion.

  • Gsk's Payables fell 1577.64% to -$21.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.9 billion, marking a year-over-year decrease of 1577.64%. This contributed to the annual value of -$22.6 billion for FY2024, which is 19741.02% down from last year.
  • According to the latest figures from Q3 2025, Gsk's Payables is -$21.9 billion, which was down 1577.64% from -$22.5 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Payables registered a high of $28.5 billion during Q4 2021, and its lowest value of -$27.0 billion during Q2 2021.
  • For the 5-year period, Gsk's Payables averaged around -$13.0 billion, with its median value being -$19.9 billion (2023).
  • As far as peak fluctuations go, Gsk's Payables soared by 7854.86% in 2022, and later crashed by 28945.32% in 2023.
  • Over the past 5 years, Gsk's Payables (Quarter) stood at $28.5 billion in 2021, then decreased by 16.85% to $23.7 billion in 2022, then dropped by 2.34% to $23.2 billion in 2023, then tumbled by 198.02% to -$22.7 billion in 2024, then grew by 3.64% to -$21.9 billion in 2025.
  • Its Payables stands at -$21.9 billion for Q3 2025, versus -$22.5 billion for Q2 2025 and -$21.5 billion for Q1 2025.